discontinuing glp-1 Many adults stop therapy within a year with low restart rates, analysis finds Patients with diabetes who remained
Description
In addition to mechanical, peptide and neurotransmitter induced GLP1 secretion
Zhao, Y., Wong, L
This personalized approach transforms GLP-1 therapy from a one-size-fits-all protocol into a precision treatment plan designed around your unique biology and reflux risk profile
Within minutes after a meal, GLP-1 is released from the L cells in the ileum and colon and regulates insulin secretion in a glucose-dependent manner
The structural design is tightly linked to the therapeutic profile, enabling the next generation of innovative GLP-1 RA drugs
